z-logo
open-access-imgOpen Access
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
Author(s) -
Valentina Boeva,
Caroline LouisBrennetot,
Agathe Peltier,
Simon Durand,
Cécile PierreEugène,
Virginie Raynal,
Heather Etchevers,
Sophie Thomas,
Alban Lermine,
Estelle DaudigeosDubus,
Birgit Geoerger,
Martin F. Orth,
Thomas G. P. Grünewald,
Elise Diaz,
Bertrand Ducos,
Didier Surdez,
Ángel M. Carcaboso,
И В Медведева,
Thomas Deller,
Valérie Combaret,
Eve Lapouble,
Gaëlle Pierron,
Sandrine Grossetête-Lalami,
Sylvain Baulande,
Gudrun Schleiermacher,
Emmanuel Barillot,
Hermann Rohrer,
Olivier Delattre,
Isabelle JanoueixLerosey
Publication year - 2017
Publication title -
nature genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 18.861
H-Index - 573
eISSN - 1546-1718
pISSN - 1061-4036
DOI - 10.1038/ng.3921
Subject(s) - neuroblastoma , biology , neural crest , enhancer , cancer research , cell type , transcription factor , cell fate determination , cell , gene , computational biology , genetics , cell culture
Neuroblastoma is a tumor of the peripheral sympathetic nervous system, derived from multipotent neural crest cells (NCCs). To define core regulatory circuitries (CRCs) controlling the gene expression program of neuroblastoma, we established and analyzed the neuroblastoma super-enhancer landscape. We discovered three types of identity in neuroblastoma cell lines: a sympathetic noradrenergic identity, defined by a CRC module including the PHOX2B, HAND2 and GATA3 transcription factors (TFs); an NCC-like identity, driven by a CRC module containing AP-1 TFs; and a mixed type, further deconvoluted at the single-cell level. Treatment of the mixed type with chemotherapeutic agents resulted in enrichment of NCC-like cells. The noradrenergic module was validated by ChIP-seq. Functional studies demonstrated dependency of neuroblastoma with noradrenergic identity on PHOX2B, evocative of lineage addiction. Most neuroblastoma primary tumors express TFs from the noradrenergic and NCC-like modules. Our data demonstrate a previously unknown aspect of tumor heterogeneity relevant for neuroblastoma treatment strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom